Impact of solid tumor history on treatment response and survival of patients with diffuse large B-cell lymphoma
10.3760/cma.j.issn.0253-2727.2019.08.003
- VernacularTitle: 实体肿瘤病史对弥漫大B细胞淋巴瘤患者的疗效和生存的影响
- Author:
Yanna MENG
1
,
2
,
3
;
Qing SHI
1
,
2
;
Shu CHENG
1
,
2
;
Li WANG
1
,
2
;
Weili ZHAO
1
,
2
Author Information
1. State Key Laboratory of Medical Genomics
2. Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
3. Xuzhou Center Hospital, Xuzhou 221009, China
- Publication Type:Journal Article
- Keywords:
Solid tumor;
Diffuse large B-cell lymphoma;
Treatment response;
Survival
- From:
Chinese Journal of Hematology
2019;40(8):639-643
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe whether the history of solid tumors affects the treatment response and survival situation of patients with diffuse large B-cell lymphoma (DLBCL) .
Methods:A retrospective study was conducted in 836 patients with DLBCL who were treated in the Department of Hematology at Ruijin Hospital from 2013 to 2018. Among them, 34 DLBCL patients who had the history of solid tumors were classified into double cancer group. From 802 patients without history of solid tumors, 68 DLBCL patients were selected as control group, using 1∶2 matching on propensity scores for age, gender, IPI score and etc. All patients included in the study had follow-up interviews through medical record and telephone for mortality from any cause. Treatment response and 3-year overall survival (OS) and progression-free survival (PFS) of two groups were analyzed.
Results:The complete remission rates after RCHOP (Rituximab+Cyclophosphamide+Vincristine+Adriamycin 50 mg/m2 or Epirubicin or Liposome Adriamycin+Prednisone) regimen were 79.4% and 67.6% in the double cancer group and the control group, respectively (P=0.210) . Among the 102 patients, 6 patients died in the double cancer group while 24 patients died in the control group and the median survival time of both two groups were not reached. The 3-year OS were (74.7±9.5) % and (63.5±6.1) % (χ2=2.791, P=0.095) , while 3-year PFS were (72.1±8.8) % and (54.3±6.4) % (χ2=1.400, P=0.237) in the double cancer group and the control group, respectively.
Conclusion:The history of solid tumors didn’t affect DLBCL patients’ treatment response and short-term survival.
